biotech · Lymphoma, Non-Hodgkin · Systemic Lupus Erythematosus · CRBU
Caribou Biosciences
Caribou Biosciences is a biotech organization headquartered in Berkeley, USA. It trades on NYSE under ticker CRBU. Primary therapeutic focus areas include Lymphoma, Non-Hodgkin, Systemic Lupus Erythematosus, Relapsed/Ref
Berkeley, USA HQ
2012 Founded
131 Employees
Public company Type
CRBU · NYSE Ticker
Company details
- Status
- Public
- HQ
- Berkeley, USA
- Founded
- 2012
- Employees
- 131
- Programs
- 4
- Drugs
- 2
- Patents
- 19
CB-011
Phase 1 · mab · Relapsed/Refractory Multiple Myeloma
CB-011 for Relapsed/Refractory Multiple Myeloma is a Phase 1 program (mab) at Caribou Biosciences with 1 ClinicalTrials.gov record(s).
Internal code CB11A
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Caribou Biosciences
- Phase
- Phase 1
- Modality
- mab
- Indication
- Relapsed/Refractory Multiple Myeloma
- Status
- active
- Trials
- 1